Figure 6.

GLUT3 and GLUT1 immunofluorescence following antisense oligodeoxynucleotide treatment. Two-cell embryos developing over 48 hr in BMOC2 and supplemented with 30 μM oligodeoxynucleotides: GLUT3 sense (A), GLUT3 antisense (B, C, D, and G), GLUT1 sense (E), GLUT1 antisense (F and H); and then probed with anti-GLUT3 (A–D and H) or anti-GLUT1 (E–G) as described. GLUT3 immunoreactivity present in sense (A) cultured embryos is abolished by GLUT3 antisense treatment (B). Highly attenuated but not fully abolished GLUT3 immunoreactivity was observed in 10% of morulae (C) and all blastocysts examined (D). The specificity of both the antibodies and the oligonucleotide treatments is shown by the persistence of GLUT1 immunoreactivity in the GLUT3 antisense-treated embryos (G) and GLUT3 immunoreactivity following GLUT1 antisense treatment (H).